Tags : Triple-Negative Breast Cancer

Clinical Trials

Roche Presents New P-III Data of Tecentriq in Triple-Negative Breast

Shots: Roche divulges results from three P-III studies of Tecentriq (atezolizumab) clinical development program in TNBC at the ESMO Virtual Congress 2020. The P-III IMpassion031 assessing Tecentriq + CT vs PBO + CT demonstrated improvement in pathological complete response (pCR: 57.6% vs 41.1%) in early TNBC patients The P-III IMpassion130 study assessing Tecentriq + nab-paclitaxel […]Read More

Biotech

Chugai Launches Tecentriq Intravenous Infusion 840mg as an Optimal Formulation

Shots: Tecentriq (atezolizumab, q2w) Intravenous Infusion 840mg has been listed on the NIH reimbursement price list and launched by Chugai as an optimal formulation to treat PD-L1-positive hormone receptor-negative and HER2-negative inoperable or recurrent BC The P-III IMpassion130 study involve assessing of Tecentriq + nab-paclitaxel (albumin-bound) vs nab-paclitaxel (albumin-bound) in patients with unresectable LA/metastatic TNBC […]Read More

Pharma

OncoSec Reports Result of Keytruda + TAVO in P-II KEYNOTE-890

Shots: The P-II KEYNOTE-890 study results involve assessing of Keytruda (200mg, IV) + TAVO (tavokinogene telseplasmid) in 25 patients with heavily pretreated, CT/radiotherapy refractory mTNBC who failed an average of 3.5 prior lines of CT The P-II KEYNOTE-890 study result:  @3mos. 20% + tumor reduction; two patients showed 66% tumor reduction including reduction of liver […]Read More

Pharma

Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-119 Study

Shots: The P-III KEYNOTE-119 study results involves assessing of Keytruda (pembrolizumab, 200mg) as monothx. vs CT (capecitabine/eribulin/gemcitabine/vinorelbine) for the 2L/3L treatment in 622 patients in ratio (1:1) with metastatic triple-negative breast cancer The P-III KEYNOTE-119 study demonstrated that it did not meet its 1EPs of OS, safety profile of Keytruda is consistent as no new […]Read More

MedTech Pharma

Roche’s Ventana PD-L1 (SP142) Receives FDA’s Approval for Identifying Triple-Negative

Shots: The approval is based on IMpassion130 study assessing Tecentriq + Abraxane vs PBO + Abraxane in patients with advanced or mTNBC with no prior therapy The Ventana PD-L1 (SP142) assay was used in Roche’s Tecentriq clinical trials to stratify patients and enhances the visual contrast of tumor-infiltrating immune cell staining The Ventana PD-L1 (SP142) […]Read More